Dr. Reddy's Laboratories shares are in focus today. The US SEC has concluded its investigation into allegations of improper payments to healthcare professionals. The regulator has decided not to recommend any enforcement action against the company. This development follows an internal probe launched by Dr. Reddy's in 2020. The company fully cooperated with the authorities during the investigation.
